Literature DB >> 35325492

Importance of establishing antibody specificity in multisystem inflammatory syndrome in newborn during the COVID-19 pandemic.

Ana Teresa Leslie1, Manar Saleh1, Naharmal Soni1, Patrick Tang2, Venkat Kallem3, Charlotte Tscherning1, Kiran More1.   

Abstract

Entities:  

Year:  2022        PMID: 35325492      PMCID: PMC9111369          DOI: 10.1111/apa.16345

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   4.056


× No keyword cloud information.
immunoglobulin G multisystem inflammatory syndrome in newborns severe acute respiratory syndrome coronavirus 2 Multisystem inflammatory syndrome in newborns (MIS‐N) has increasingly been reported in patients with the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). ,  MIS‐N can be secondary to immune‐mediated injuries, due to transplacental maternal or neonatal antibodies produced during the infection. This process is similar to multisystem inflammatory syndrome in children.  Transplacental transfer of maternal SARS‐CoV‐2 immunoglobulin G (IgG) antibodies can be protective, but sometimes in‐utero transfer of these antibodies, concomitant other inflammatory cytokines, may trigger MIS‐N. Increased viral transmission and mass vaccination have increased SARS‐CoV‐2 seroprevalence, and babies are increasingly being born with positive antibodies.  We describe a baby with multi‐organ dysfunction, due to placental abruption, but confounded by SARS‐CoV‐2 antibodies consistent with MIS‐N. Parental consent was provided. A male baby weighing 2,690 kg was born at 33 + 5 weeks to a primipara mother with placenta previa. She was an unvaccinated nurse, with potential exposure to SAR‐CoV‐2, who tested negative before labour. The baby was born vigorous, but pale, and required intubation at 11 min. His cord gas was normal, but he had low haemoglobin (11 g/L). The initial treatment included mechanical ventilation, empirical antibiotics, fluid management, packed red blood cells (PRBC) and fresh frozen plasma (FFP) transfusions for abnormal coagulation. His renal function started to deteriorate 12 h after transfusion, with no urine output since birth and increasing hyperkalaemia. At 24 h, he was transferred to our quaternary hospital, in case he needed peritoneal dialysis. He presented with severe multi‐organ dysfunction, with respiratory distress needing ventilation and cardiac compromise with low blood pressure. An echocardiogram suggested mild left ventricular dysfunction and exponential elevation of cardiac biomarkers, N‐terminal‐pro‐B‐type natriuretic peptide (>70,000 pg/ml) and troponin‐T (2,046 ng/ml), suggesting myocardial injury. He had acute renal failure, with elevated serum potassium (9.5 mmol/L) and rising urea and creatinine and needed peritoneal dialysis from 3 to 11 weeks of life. Gastric bleeding, with abnormal clotting and platelet levels, required multiple vitamin K doses, PRBC, cryoprecipitate, FFP and platelet transfusions. His liver enzymes were significantly elevated on admission, but gradually declined, with extensive necrosis visible on his abdominal ultrasound. The baby was not encephalopathic, with a discontinuous background on amplitude‐integrated electroencephalogram and normal cerebral near‐infrared spectroscopy. Brain magnetic resonance imaging on day 19 showed minor multifocal deep white matter abnormalities. All his inflammatory markers were markedly elevated: Serum ferritin (3,825 mcg/L), lactate dehydrogenase (>1,200 IU/L), procalcitonin (7.21 ng/ml) and D‐Dimer concentration (>7,500). Multiple nasopharyngeal swabs, tracheal aspirate and stool samples tested negative for SARS‐CoV‐2, and he and his mother were negative for SARS‐CoV‐2 immunoglobulin M antibodies. However, he tested positive for immunoglobulin G (IgG) antibodies against SARS‐CoV‐2 with titres of 210 and 155 BAU/ml on days 3 and 11 of life. His mother's level was 17.9 BAU/ml. We suspected MIS‐N, as SARS‐CoV‐2 IgG was present, and he received immunomodulatory therapy from day 2 of life, with a single dose of intravenous immunoglobulin (1 g/kg) and daily methylprednisolone (1 mg/kg). Enzyme‐linked immunosorbent assays showed that he and his mother had antibodies against the SARS‐CoV‐2 spike protein, but not nucleoprotein. MIS‐N was thus ruled out, and immunomodulator therapy discontinued. The baby was extubated at 3 weeks of life, but his liver failure continued. His clinical condition progressively worsened, and he died 93 days after birth. The patient's severe multi‐organ dysfunction was related to placental abruption, but the degree of bleeding was unclear at birth. High levels of inflammatory markers, cardiac biomarkers and mild left ventricular dysfunction on admission, during the pandemic, suggested MIS‐N. He tested negative for the virus, but his mother was positive for SARS‐CoV‐2 IgG antibodies and his antibodies were 6 times her levels. The initial immunomodulatory treatment, due to suspected MIS‐N, was stopped after we established the antigen specificity of the antibodies. The results were inconsistent with natural infection, and vaccination‐derived antibodies from transfusions were suspected. The mother's serum sample was collected after three blood transfusions, and the infant had received multiple blood product transfusions before his serology sample. Both had received transfusions from vaccinated donors which were traced from blood bank. The increased prevalence of SARS‐CoV‐2 antibodies in blood donations has been reported.  Just over a quarter (28%) of Qatar residents were fully vaccinated using the Pfizer and Moderna messenger ribonucleic acid vaccines at the time of the child's hospitalisation. Detecting antibodies against the spike protein, but not nucleoprotein, argued against a natural infection. The pandemic and the baby's critical neonatal inflammatory response made it vital to rule out MIS‐N, and the antigen specificity of SARS‐CoV‐2 played an important role in this process. Figure 1 shows the mechanism of MIS‐N and potential sources of SARS‐CoV‐2 antibodies.
FIGURE 1

Mechanisms of exhibiting SARS‐CoV‐2 antibodies in newborn.

Source: Anti‐N antibody, anti‐nuclear protein antibody; Anti‐RBD antibody, anti‐receptor‐binding domain antibody; Anti‐S antibody, anti‐spike protein antibody; FFP, fresh frozen plasma; mRNA, messenger RNA (ribo nucleic acid); PRBC, packed red blood cells

Mechanisms of exhibiting SARS‐CoV‐2 antibodies in newborn. Source: Anti‐N antibody, anti‐nuclear protein antibody; Anti‐RBD antibody, anti‐receptor‐binding domain antibody; Anti‐S antibody, anti‐spike protein antibody; FFP, fresh frozen plasma; mRNA, messenger RNA (ribo nucleic acid); PRBC, packed red blood cells Neonatal multi‐organ dysfunction can be severe, but many conditions can masquerade as MIS‐N. SARS‐CoV‐2 antibodies may cause MIS‐N, but they could also be incidental bystanders and all possibilities must be thoroughly investigated.

FUNDING INFORMATION

None.

CONFLICT OF INTEREST

None.
  5 in total

1.  Perinatal SARS-CoV-2 Infection and Neonatal COVID-19: A 2021 Update.

Authors:  Deepika Sankaran; Natasha Nakra; Ritu Cheema; Dean Blumberg; Satyan Lakshminrusimha
Journal:  Neoreviews       Date:  2021-05

2.  Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.

Authors:  Jefferson M Jones; Mars Stone; Hasan Sulaeman; Rebecca V Fink; Honey Dave; Matthew E Levy; Clara Di Germanio; Valerie Green; Edward Notari; Paula Saa; Brad J Biggerstaff; Donna Strauss; Debra Kessler; Ralph Vassallo; Rita Reik; Susan Rossmann; Mark Destree; Kim-Anh Nguyen; Merlyn Sayers; Chris Lough; Daniel W Bougie; Megan Ritter; Gerardo Latoni; Billy Weales; Stacy Sime; Jed Gorlin; Nicole E Brown; Carolyn V Gould; Kevin Berney; Tina J Benoit; Maureen J Miller; Dane Freeman; Deeksha Kartik; Alicia M Fry; Eduardo Azziz-Baumgartner; Aron J Hall; Adam MacNeil; Adi V Gundlapalli; Sridhar V Basavaraju; Susan I Gerber; Monica E Patton; Brian Custer; Phillip Williamson; Graham Simmons; Natalie J Thornburg; Steven Kleinman; Susan L Stramer; Jean Opsomer; Michael P Busch
Journal:  JAMA       Date:  2021-10-12       Impact factor: 56.272

3.  Multisystem inflammatory syndrome in a neonate, temporally associated with prenatal exposure to SARS-CoV-2: a case report.

Authors:  Mahesh Kappanayil; Suma Balan; Sujata Alawani; Satish Mohanty; Sreelakshmi P Leeladharan; Sreja Gangadharan; Jessin P Jayashankar; Soumya Jagadeesan; Anil Kumar; Atul Gupta; Raman Krishna Kumar
Journal:  Lancet Child Adolesc Health       Date:  2021-03-04

4.  Multisystem inflammatory syndrome in neonates (MIS-N) associated with SARS-CoV2 infection: a case series.

Authors:  Kiran More; Sheila Aiyer; Ashish Goti; Manan Parikh; Samir Sheikh; Gaurav Patel; Venkat Kallem; Roopali Soni; Praveen Kumar
Journal:  Eur J Pediatr       Date:  2022-01-14       Impact factor: 3.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.